Skip to main content
. Author manuscript; available in PMC: 2021 May 12.
Published in final edited form as: Small. 2019 Feb 13;15(12):e1804452. doi: 10.1002/smll.201804452

Figure 5.

Figure 5.

Antitumor activity of ABD–Dox. BALB/c and nude BALB/c mice bearing A,B) syngeneic C26 and C–E) xenograft MIA PaCa-2 tumors, respectively, were treated on day 0 with ABD–Dox (10 and 20 mg Dox equiv. kg−1 BW), AlDox (20 mg Dox equiv. kg−1 BW), and free Dox (10 mg kg−1 BW). A,C) Tumor volume over 100 days after treatment. B,D) Kaplan–Meier cumulative survival of mice over 100 days post-treatment. E) Tumor-free time during the 100-day span after the treatment of mice with MIA PaCa-2 xenografts. Data are presented as mean ± SEM, n = 7–9, A,C) paired one-way ANOVA and Tukey’s test, B,D) log-rank (Mantel–Cox) test, E) one-way ANOVA and Tukey’s test, *P < 0.05, **P < 0.01, and ***P < 0.001.